Ingesting, integrating, standardizing, cleaning, coding, and analyzing disparate data sources creates complexity.
When optimizing your study practice, it is vital to evaluate every trial phase in context.
While new guidance has created a much needed sense of urgency to define a risk-based monitoring approach to clinical trials, there is one critical area of monitoring that cannot be ignored.
Yesterday we discussed how researchers are trying to incorporate new biomarker data into studies, which can generate a new set of hurdles for clinical development programs. It's clear that overcoming these challenges starts with integration.